BDNF and fibromyalgia: The ability of ketamine to modulate NMDAR, glutaminergic signaling, BDNF, descending inhibition, and inflammation and thereby result in a reduction of central sensitization may provide a comprehensive approach for the management of patients with fibromyalgia.